Background to GeneICE & Eurostars In June 2009, ValiRx, as the leading partner of an international consortium of three companies, was awarded a two year grant by Eurostar against substantial competition from across Europe, to develop its GeneICE technology (???GeneICE??? or ???Gene inactivation by chromatin engineering???), in which ???rebellious genes???, which cause problems such as cancer and p